Real-life effectiveness of tezepelumab in severe asthma
Main Article Content
Keywords
Tezepelumab, Severe asthma, real-life study
Abstract
Background: Tezepelumab is a human monoclonal antibody which inhibits the cytokine thymic stromal lymphopoietin and is effective in different asthma endotypes.
Methods: This is a prospective, multicenter study of the Register of Severe Asthma of the Region of Murcia (RE-ASGRAMUR) Group performed under routine clinical practice conditions.
Results: We present a series of 57 patients who completed at least 6 months of treatment with tezepelumab. The exacerbations decreased from a baseline mean of 2.63 in the previous year to a mean annualized rate of 0.38 after 6 months of tezepelumab (85.6% decrease). The Asthma Control Test score increased by 5.3 points, and the Mini Asthma Quality of Life Questionnaire score increased by 0.94 points. Regarding lung function, we obtained a significant increase of 188 mL in forced expiratory volume in 1 s and 166 mL in forced vital capacity. Finally, type-2 (T2) biomarkers, such as eosinophils and nitric oxide, showed a significant decrease. We compared the results in patients with or without previous biological treatment as well as in patients with or without allergy sensitization, and we did not obtain significant differences in any variable.
Conclusions: Tezepelumab is an effective treatment for severe asthma, lessening exacerbations, controlling the disease, and improving quality of life and lung function in patients with and without high T2 biomarkers, regardless of previous biological treatment.
References
2. Miralles-López JC, Antolín-Amérigo D, García-Moguel I, Domínguez-Ortega J, Delgado-Romero J, Quirce S. Positioning of tezepelumab in severe asthma. J Investig Allergol Clin Immunol. 2024;34(1):1–11. https://doi.org/10.18176/jiaci.0949
3. Diver S, Khalfaoui L, Emson C, Wenzel SE, Menzies-Gow A, Wechsler ME, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to severe uncontrolled asthma (CASCADE): A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9:1299–312. https://doi.org/10.1016/S2213-2600(21)00226-5
4. Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377:936–46. https://doi.org/10.1056/NEJMoa1704064
5. Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384:1800–9. https://doi.org/10.1056/NEJMoa2034975
6. Panettieri Jr R, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: One drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219–36. https://doi.org/10.2147/JAA.S342391
7. Biener L, Mümmler C, Hinze CA, Suhling H, Korn S, Fisser C, et al. Real-world data on tezepelumab in patients with severe asthma in Germany. J Allergy Clin Immunol Pract. 2024;12:2399–407. https://doi.org/10.1016/j.jaip.2024.05.052
8. Miralles-López JC, Andújar-Espinosa R, Bravo-Gutierrez FJ, Cabrejos-Perotti S, Ramírez-Hernández M, Díaz-Chantar C, et al. Tezepelumab in patients with severe asthma: Response at 3 months. J Investig Allergol Clin Immunol. 2024 Nov 25:0. Epub ahead of print. https://doi.org/10.18176/jiaci.1041.
9. Alvarez-Gutierrez FJ, Blanco-Aparicio M, Casas-Maldonado F, Plaza V, González-Barcala FJ, Carretero-Gracia JA, et al. Documento de consenso de asma grave en adultos. Actualizacion. 2022 [Consensus document on severe asthma in adults. Update 2022]. Open Respir Arch. 2022;4(3):100192. https://doi.org/10.1016/j.opresp.2022.100192
